Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Trends in Cancer Research   Volumes    Volume 11 
Early-stage breast cancer treatment in the US over 20 years: Changes in therapy and short-term cancer survival
Linda C. Harlan, Lindsey Enewold, Jennifer L. Stevens
Pages: 141 - 156
Number of pages: 16
Trends in Cancer Research
Volume 11 

Copyright © 2016 Research Trends. All rights reserved

Early-stage breast cancer adjuvant therapy and survival have changed over the last 20 years. Using the National Cancer Institute’s population-based patterns of care studies, we examined adjuvant multi-agent chemotherapy and endocrine therapy utilization and cancer survival among women diagnosed with early-stage, invasive breast cancer in 1990, 1995, 2000, 2005, and 2010 who were sampled from Surveillance, Epidemiology and End Results (SEER) registries. Medical records were re-abstracted and treatment verified with physicians. Logistic regression and Cox proportional hazards regression were utilized to identify factors associated with treatment and 3-yr cancer survival. Utilization of multi-agent chemotherapy increased, regardless of nodal and estrogen receptor (ER) status but most notably among women with ER-positive tumors. There were significant changes in preferred chemotherapy regimen overtime: from cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 1990 to anthracycline, cyclophosphamide and taxane (AC-T) in 2000 to cyclophosphamide and taxane (TC) in 2010. Endocrine therapy decreased among women with ER-negative tumors and increased among women with node-negative, ER-positive tumors. Utilization of aromatase inhibitors rapidly increased. More recent diagnosis year and younger age were consistently associated with receipt of adjuvant therapy. Poorer survival was associated with earlier diagnosis year, older age, being non-Hispanic black, having more extensive disease and not receiving endocrine therapy. In conclusion, adjuvant therapy utilization and 3-year cancer survival increased over time. Whether the expanded use of genomic testing and personalize medicine influences the national trends in adjuvant therapy and survival remains to be seen.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms